Article Text

PDF
Nitrous oxide analgesia during retinopathy screening: a randomised controlled trial
  1. Romain Mandel1,
  2. Nabeel Ali1,
  3. John Chen2,
  4. Ivan John Galic2,
  5. Linda Levesque3
  1. 1Department of Pediatrics, Division of Neonatology, McGill University Health Centre, Montreal, Quebec, Canada
  2. 2Department of Ophthalmology, McGill University Health Centre, Montreal, Quebec, Canada
  3. 3Department of Respiratory Therapy, Jewish General Hospital, Montreal, Quebec, Canada
  1. Correspondence to Dr Nabeel Ali, Department of Pediatrics, Division of Neonatology, McGill University Health Centre, Royal Victoria Hospital, Room c7.80, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada; nabeel.ali{at}mcgill.ca

Abstract

Objectives To determine if the addition of an inhaled equimolar mixture of nitrous oxide (N2O) and oxygen (EMONO) would produce superior pain relief to standard pharmacological and non-pharmacological measures during eye examination screening for retinopathy of prematurity (ROP) in premature infants.

Study design A randomised, double-blind controlled trial was conducted.

Setting Royal Victoria Hospital, a tertiary neonatal intensive care unit in Montreal, Canada.

Patients Stable spontaneously breathing premature infants with birth weights less than 1500 g or gestation of 30 weeks and less.

Intervention During the eye examination, all infants were swaddled, received oral sucrose and topical anaesthetics. Control group infants received a mixture of 50% oxygen and 50% nitrogen (n=18) administered by nasal cannula, while the intervention group received EMONO (50% oxygen and 50% N2O).

Main outcome measures Pain was assessed by the premature infant pain profile (PIPP).

Results The mean PIPP score at speculum insertion in the control group (8.4, 95% CI 7.6 to 9.3) was comparable with the EMONO group (8.5, 95% CI 7.3 to 9.8) with a p value of 0.94. There were no significant differences in heart rate or saturation between the two groups. EMONO inhalation was tolerated without any measured side effects.

Conclusion EMONO does not produce any additional pain relief over currently used measures during ROP screening eye examinations. Systematically combining pharmacological and non-pharmacological treatment modalities appears to be the best option until newer treatments are proven effective.

Clinical trials registration number NCT00623220

Statistics from Altmetric.com

Footnotes

  • Funding This research was funded by a grant from the Montreal Children's Hospital Research Institute.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Montreal Children's Hospital Research Ethics Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.